Market revenue in 2023 | USD 1,459.9 million |
Market revenue in 2030 | USD 2,645.2 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Jardiance (empagliflozin) |
Fastest growing segment | Inpefa (sotagliflozin) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Inpefa (sotagliflozin) , Qtern (dapagliflozin/saxagliptin), Other SGLT2 Inhibitors |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sglt2 inhibitors market will help companies and investors design strategic landscapes.
Jardiance (empagliflozin) was the largest segment with a revenue share of 52.61% in 2023. Horizon Databook has segmented the Germany sglt2 inhibitors market based on jardiance (empagliflozin), farxiga (dapagliflozin), invokana (canagliflozin), inpefa (sotagliflozin) , qtern (dapagliflozin/saxagliptin), other sglt2 inhibitors covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany sglt2 inhibitors market , including forecasts for subscribers. This country databook contains high-level insights into Germany sglt2 inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account